MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Simulations Plus Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.95 -0.17

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.93

Max

12.05

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4M

676K

Pardavimai

961K

18M

Dividendų pajamingumas

0.48

Pelno marža

3.67

Darbuotojai

212

EBITDA

-3M

2.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+58.47% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.48%

2.45%

Kitas uždarbis

2026-04-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-139M

229M

Ankstesnė atidarymo kaina

12.12

Ankstesnė uždarymo kaina

11.95

Naujienos nuotaikos

By Acuity

58%

42%

293 / 349 reitingas Healthcare

Simulations Plus Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-03 04:27; UTC

Svarbiausios naujienos

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026-04-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 18:30; UTC

Svarbiausios naujienos

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026-04-03 18:14; UTC

Rinkos pokalbiai

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026-04-03 17:50; UTC

Rinkos pokalbiai

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026-04-03 17:44; UTC

Įsigijimai, susijungimai, perėmimai

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026-04-03 16:50; UTC

Svarbiausios naujienos

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026-04-03 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 16:12; UTC

Uždarbis

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-04-03 15:20; UTC

Svarbiausios naujienos

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026-04-03 15:08; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026-04-03 14:11; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026-04-03 12:56; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026-04-03 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 08:01; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 08:01; UTC

Rinkos pokalbiai

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026-04-03 07:45; UTC

Rinkos pokalbiai

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026-04-03 06:17; UTC

Rinkos pokalbiai

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026-04-03 06:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 04:33; UTC

Rinkos pokalbiai

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026-04-03 04:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-03 04:01; UTC

Rinkos pokalbiai

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026-04-03 02:01; UTC

Rinkos pokalbiai

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026-04-03 01:59; UTC

Rinkos pokalbiai

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026-04-03 01:44; UTC

Rinkos pokalbiai

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026-04-03 01:22; UTC

Rinkos pokalbiai

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Akcijų palyginimas

Kainos pokytis

Simulations Plus Inc Prognozė

Kainos tikslas

By TipRanks

58.47% į viršų

12 mėnesių prognozė

Vidutinis 19 USD  58.47%

Aukščiausias 19 USD

Žemiausias 19 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Simulations Plus Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

293 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat